Taysha Gene Therapies, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • June 26th, 2024 • Taysha Gene Therapies, Inc. • Biological products, (no disgnostic substances)
Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom you are acting as the representatives (the “Representatives”), (i) an aggregate of 14,361,113 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 5,000,000 additional shares (the “Optional Shares”) of common stock, par value $0.00001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”), and (ii) warrants of the Company to purchase 18,972,221 shares of Stock at an exercise price equal to $0.001 per share (the “Pre-Funded Warrants” and, together with the Firm Shares, the “Firm Securities”). As used herein, “Warrant Shares” means the shares of Stock issuable upon exercise of the Pre-F
